HLS Therapeutics (TSE:HLS) Trading 2.2% Higher – Should You Buy?

HLS Therapeutics Inc. (TSE:HLS)’s stock price traded up 2.2% on Tuesday . The company traded as high as C$4.23 and last traded at C$4.20. Approximately 9,200 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 20,629 shares. The stock had previously closed at C$4.11.

HLS Therapeutics Stock Up 2.2%

The firm’s 50 day moving average is C$4.39 and its 200-day moving average is C$4.49. The firm has a market cap of C$131.35 million, a PE ratio of -13.12 and a beta of -0.15. The company has a quick ratio of 1.01, a current ratio of 1.00 and a debt-to-equity ratio of 75.00.

HLS Therapeutics (TSE:HLS) last released its earnings results on Friday, May 15th. The company reported C($0.10) EPS for the quarter. The firm had revenue of C$17.88 million during the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%. As a group, equities research analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.